<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="361">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01180790</url>
  </required_header>
  <id_info>
    <org_study_id>ACH625-003</org_study_id>
    <secondary_id>2010-022092-65</secondary_id>
    <nct_id>NCT01180790</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in HCV Positive Subjects</brief_title>
  <official_title>A Phase IIa, Randomized, Double-blind (Subject and Investigator Blind, Sponsor Open), Placebo-controlled Trial to Evaluate the Safety, Tolerability and Antiviral Activity of Oral ACH-0141625 in Combination With Pegylated Interferon Alpha-2a and Ribavirin in Two Segments, After 28 Days of Dosing and, Subsequently, After 12 Weeks of Dosing in Subjects With Chronic Hepatitis C Virus Genotype 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achillion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Achillion Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate safety, tolerability and antiviral response of ACH-0141625 compared to Standard of
      Care in HCV positive subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Segment 1: Safety</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Segment 1: Percentage of subjects with the following: adverse events, abnormal laboratory safety tests, dose reductions, interruptions, and discontinuations. Criteria for abnormal laboratory safety tests: treatment-emergent worsening DAIDs graded laboratory tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Segment 1 : Rapid Viral Response at Week 4 (RVR4)</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary efficacy endpoint for Segment 1 of the study was the percentage of subjects in each treatment group achieving RVR at Week 4 (HCV RNA&lt; or equal to LOQ at the Week 4 visit).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Segment 2: Safety</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Segment 2: Percentage of Subjects with the following: adverse events, abnormal laboratory safety tests and dose reductions, interruptions and discontinuations. Criteria for abnormal laboratory safety tests: treatment-emergent worsening DAIDs graded laboratory tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Segment 2: Complete Early Virologic Response (cEVR)</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary efficacy endpoint for Segment 2 of the study was the percentage of subjects achieving cEVR (complete early virologic response), defined as undetectable HCV RNA at Week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Segment 1: Complete Early Virologic Response (cEVR)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>For Segment 1, the percentage of subjects in the virology population that achieved cEVR (complete early virologic response), defined as undetectable HCV RNA at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Segment 2: RVR4 (Rapid Viral Response at 4 Weeks)</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>For Segment 2, the percentage of subjects in the virology population that achieved RVR4, defined as HCV RNA&lt; or equal to LOQ at the Week 4 visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Segment 1 and Segment 2: End of Treatment Response</measure>
    <time_frame>Week 48 (Segment 1); Week 24 (Segment 2)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of the Virology Population subjects that were reported as undetectable HCV RNA at the completion of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Segment 1 and Segment 2: Sustained Virologic Response 12 Weeks ( Three Months Post Dosing) (SVR12)</measure>
    <time_frame>3 months post dosing</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of the Virology Population subjects that achieved sustained virologic response, defined as HCV RNA &lt; LOQ, at 12 weeks (three months) post dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Segment 1 and Segment 2: Sustained Virologic Response ( Six Months Post Dosing) (SVR24)</measure>
    <time_frame>6 months post dosing</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of the Virology Population subjects that achieved sustained virologic response, defined as HCV RNA &lt; LOQ, six months post dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Segment 1 and Segment 2: HCV RNA Change From Baseline</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>The mean change from baseline in log10 HCV RNA level by visit for the virology population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Segment 1 and Segment 2: HCV RNA Change From Baseline</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in log10 HCV RNA level by visit.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Segment 1: 200 mg ACH-0141625</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg ACH-0141625 for 28 days plus Peg-IFN alpha-2a and ribavirin for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Segment 1: 400 mg ACH-0141625</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg ACH-0141625 for 28 days plus Peg-IFN alpha-2a plus ribavirin for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Segment 1: 800 mg ACH-0141625</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg ACH-0141625 for 28 days plus Peg-IFN alpha-2a plus ribavirin for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Segment 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 28 days plus Peg-IFN alpha-2a plus ribavirin for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Segment 2: 200 mg ACH-0141625</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg ACH-0141625 for 12 weeks plus Peg-IFN and ribavirin for up to a total of 24 or 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Segment 2 : 400 mg ACH-0141625</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg ACH-0141625 for 12 weeks plus Peg-IFN and ribavirin for up to a total of 24 or 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Segment 2 : 800 mg ACH-0141625</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg ACH-0141625 for 12 weeks plus Peg-IFN and ribavirin for up to a total of 24 or 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH-0141625 (Sovaprevir)</intervention_name>
    <description>200 mg oral capsule once daily</description>
    <arm_group_label>Segment 1: 200 mg ACH-0141625</arm_group_label>
    <arm_group_label>Segment 2: 200 mg ACH-0141625</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH-0141625 (Sovaprevir)</intervention_name>
    <description>400 mg oral capsule once daily</description>
    <arm_group_label>Segment 1: 400 mg ACH-0141625</arm_group_label>
    <arm_group_label>Segment 2 : 400 mg ACH-0141625</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH-0141625 (Sovaprevir)</intervention_name>
    <description>800 mg oral capsule once daily</description>
    <arm_group_label>Segment 1: 800 mg ACH-0141625</arm_group_label>
    <arm_group_label>Segment 2 : 800 mg ACH-0141625</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Powder in capsule once daily</description>
    <arm_group_label>Segment 1: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Interferon alpha-2a</intervention_name>
    <description>180 ug once a week by subcutaneous injection</description>
    <arm_group_label>Segment 1: 200 mg ACH-0141625</arm_group_label>
    <arm_group_label>Segment 1: 400 mg ACH-0141625</arm_group_label>
    <arm_group_label>Segment 1: 800 mg ACH-0141625</arm_group_label>
    <arm_group_label>Segment 1: Placebo</arm_group_label>
    <arm_group_label>Segment 2: 200 mg ACH-0141625</arm_group_label>
    <arm_group_label>Segment 2 : 400 mg ACH-0141625</arm_group_label>
    <arm_group_label>Segment 2 : 800 mg ACH-0141625</arm_group_label>
    <other_name>Peg-INF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>400 mg or 600 mg (am) and 600 mg (pm) capsules taken orally twice daily</description>
    <arm_group_label>Segment 1: 200 mg ACH-0141625</arm_group_label>
    <arm_group_label>Segment 1: 400 mg ACH-0141625</arm_group_label>
    <arm_group_label>Segment 1: 800 mg ACH-0141625</arm_group_label>
    <arm_group_label>Segment 1: Placebo</arm_group_label>
    <arm_group_label>Segment 2: 200 mg ACH-0141625</arm_group_label>
    <arm_group_label>Segment 2 : 400 mg ACH-0141625</arm_group_label>
    <arm_group_label>Segment 2 : 800 mg ACH-0141625</arm_group_label>
    <other_name>Ribasphere</other_name>
    <other_name>Copegus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 18 years and older

          -  Chronic hepatitis C Genotype 1 (as specified in the protocol)

          -  Treatment naive

          -  Females who are post-menopausal and amenorrheic must have a FSH at screening. Females
             of child bearing potential must have a negative pregnancy test at screening and
             baseline. Females must use a non hormonal method of contraception and must agree not
             to get pregnant during the study and for six months following the discontinuation of
             SOC.

          -  Fertile males must agree to use a condom and his female partner must agree to use one
             or more methods of contraception. Males must not donate sperm during the study and
             three months following the last exposure to RBV.

        Exclusion Criteria:

          -  BMI &gt;36 kg/m2

          -  Pregnant or nursing females: or females of childbearing potential not willing to
             comply with contraceptive measures per protocol. Men whose female partners are
             pregnant or contemplating pregnancy. - Coinfection with HBV and/or HIV

          -  Other significant disease including liver disease

          -  History of drug or alcohol dependence or addiction within the past 6 months

          -  History of participation in a clinical trial with a protease inhibitor or previous
             treatment with a protease inhibitor, where at least one dose of the protease
             inhibitor was consumed.

          -  Use of herbal or homeopathic products, illicit drugs, cytochrome P450 (CYP 3A4/5
             substrates, inducers or inhibitors, hormonal methods of contraception,
             corticosteroids, immunosuppressive, or cytotoxic agents within 28 days of first dose
             of study drug.

          -  Have a clinically significant laboratory abnormality at screening (as specified in
             protocol).

          -  Segment 1: Subjects with any history of decompensated liver disease defined as
             cirrhotic subjects with a Child-Pugh score of &gt; or = to 7. Segment 2: Subjects who
             have had a liver biopsy that shows bridging fibrosis or cirrhosis.

          -  Nonalcoholic steatohepatitis if ballooning degeneration or Mallory bodies are present
             on liver biopsy.

          -  Subjects, who prematurely discontinued, interrupted or dose reduced prior Peg-IFN and
             Ribavirin therapy, due to noncompliance or safety issues.

          -  Encephalopathy or altered mental status of any etiology.

          -  History of moderate, severe or uncontrolled psychiatric disease (as specified in
             protocol).

          -  History of malignancy of any organ system treated or untreated within the past 5
             years.

          -  Use of colony stimulating factor agents within 90 days prior to baseline.

          -  History of seizure disorder.

          -  History of known coagulopathy including hemophilia.

          -  Clinically of significant findings on fundoscopic or retinal examination at screening

          -  History of immunologically mediate disease.

          -  History of clinical evidence of chronic cardiac disease (as specified in protocol)

          -  Received concomitant systemic antibiotic, antifungals or antivirals for the treatment
             of active infection within 14 days prior to the first dose of the study drug (as
             specified in protocol)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hetal Kocinsky, MD</last_name>
    <role>Study Director</role>
    <affiliation>Achillion Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pointe West Infectious Disease</name>
      <address>
        <city>Brandenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince and Associates Clinical Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Impact Clinical Trials</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Texas Research Institute</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamo Medical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon Secours St. Mary's Hospital of Richmond</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive and Liver Diseas Specialists</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edgem</city>
        <state>Antwerp</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Jolimont-Lobbes</name>
      <address>
        <city>Haine-Saint-Paul</city>
        <state>Hainaut</state>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>http://studyforhepc.com/</url>
    <description>Recruitment site for potential subjects</description>
  </link>
  <verification_date>September 2014</verification_date>
  <lastchanged_date>September 8, 2014</lastchanged_date>
  <firstreceived_date>August 11, 2010</firstreceived_date>
  <firstreceived_results_date>July 29, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>Hepatitis C Genotype 1</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
